Medical Properties Trust, Inc. · NYSE:MPT
Medical Properties Trust — Proxy Contest (May 2024)
9 slides from Medical Properties Trust's proxy contest presentation, May 22, 2024
Slide 1: Supplemental Proxy Materials May 22, 2024
Supplemental Proxy Materials May 22, 2024
Slide 2: Supplemental Proxy Materials
Supplemental Proxy Materials In addition to the materials presented in the 2024 Proxy Statement, we are providing this supplemental information to ask for your support at the Annual Meeting on Proposal 3, which asks stockholders to approve, on an advisory basis, our named executive officer compensat
Slide 3: Supplemental Say-on-Pay Road Map
Supplemental Say-on-Pay Road Map Key Considerations Highlights Our Compensation Program Worked As Designed and Reduced CEO Compensation in Line with Performance If the stock values in the Summary Compensation Table were adjusted to reflect the value of shares that our CEO actually vested in and not
Slide 4: Our Program Works: Key CEO Compensation Statistics
Our Program Works: Key CEO Compensation Statistics 2023 Realizable Compensation 2023 Compensation Actually Paid -48% -93% As compared to approved compensation for 2023(1) As compared to the Summary Compensation Table ($8.4mm Realizable v. $16.3mm Approved) ($1.2mm CAP v. $17.9mm Summary Comp) Value
Slide 5: Compensation Changes for 2024
In recognition of lower Say-on-Pay support in 2023 and to further align executives with shareholders, we have made the following changes to CEO compensation in 2024: Target compensation reduced by 9% No increase to cash compensation since 2020 Equity awards redesigned Performance-based equity accoun
Slide 6: Response to ISS Voting Recommendation
Contrary to the ISS voting recommendation, our Board of Directors recommends that our stockholders vote FOR the “Say-on-Pay” proposal based on (i) the additional materials presented within this presentation, and (ii) the following response to ISS’s key takeaways on our compensation program: Rigor of
Slide 7: Magnitude of CEO's LTI Opportunity
Magnitude of CEO’s LTI Opportunity Our CEO did not receive an increase to his annual equity award value between 2020 and 2023 and as previously highlighted, our CEO’s 2024 LTI Target Opportunity was reduced by 11% (resulting in a 9% reduction to his total target compensation) Additionally, our CEO’s
Slide 8: Conclusion
CONCLUSION We urge our stockholders to carefully review our Proxy statement and the additional materials provided in determining the reasonableness and appropriateness of our compensation program While 2023 represented a more challenging environment, we continue to focus on generating long-term valu
Slide 9: At the Very Heart of Healthcare
AT THE VERYHEART OF HEALTHCARE®